ImmunityBio, Inc. - Common Stock (NQ:IBRX)

8.480 +0.660 (+8.44%)

Streaming Delayed Price Updated: 2:33 PM EDT, Mar 13, 2026 Add to My Watchlist

Price and Volume

Volume	24,683,835
Open	8.210
Bid (Size)	8.480 (1,800)
Ask (Size)	8.490 (500)
Prev. Close	7.820
Today's Range	8.200 - 8.910
52wk Range	1.830 - 12.43
Shares Outstanding	391,156,513
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

IBRX Stock Rises 3% Pre-Market: ImmunityBio Reports Breakthrough In NK Cell Therapy Production ↗

Today 8:07 EDT

ImmunityBio also completed a Phase 1 study combining its memory cytokine-enhanced NK cell therapy with ANKTIVA.

Via Stocktwits

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Today 7:30 EDT

From ImmunityBio, Inc.

Via Business Wire

Performance

YTD	+319.8%	+319.8%
1 Month	+29.3%	+29.3%
3 Month	+287.2%	+287.2%
6 Month	+227.4%	+227.4%
1 Year	+195.5%	+195.5%

More News

IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact ↗

March 12, 2026

Via Stocktwits

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗

March 12, 2026

Via MarketBeat

IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst ↗

March 11, 2026

Via Stocktwits

IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗

March 09, 2026

Via Stocktwits

Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews ↗

March 09, 2026

Via Stocktwits

IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva ↗

March 06, 2026

Via Stocktwits

Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗

March 05, 2026

Via The Motley Fool

IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗

March 05, 2026

Via Stocktwits

IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside ↗

March 04, 2026

Via Stocktwits

ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth

March 04, 2026

Via MarketMinute

Dow, S&P 500, Nasdaq Futures Slip As Middle East War Fuels Oil Rally: Why MU, IBRX, BATL, DJT, SE Are On Traders’ Radar Today ↗

March 03, 2026

Via Stocktwits

IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗

March 03, 2026

Via Stocktwits

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

Via Stocktwits

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗

March 02, 2026

Via Stocktwits

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

February 27, 2026

From ImmunityBio

Via Business Wire

IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds ↗

February 26, 2026

Via Stocktwits

IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial ↗

February 26, 2026

Via Stocktwits

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

February 26, 2026

From ImmunityBio, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗

February 26, 2026

Via Stocktwits

ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally ↗

February 26, 2026

Via Stocktwits

IBRX Stock Rallies Into Trump’s Big SOTU Night — Here’s What Traders Think Could Fuel The Next Move ↗

February 24, 2026

Via Stocktwits

IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth ↗

February 23, 2026

Via Stocktwits

Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700% ↗

February 23, 2026

Via The Motley Fool

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?

Yes, ImmunityBio, Inc. - Common Stock is publicly traded.

What exchange does ImmunityBio, Inc. - Common Stock trade on?

ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ImmunityBio, Inc. - Common Stock?

The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market

What is the current price of ImmunityBio, Inc. - Common Stock?

The current price of ImmunityBio, Inc. - Common Stock is 8.480

When was ImmunityBio, Inc. - Common Stock last traded?

The last trade of ImmunityBio, Inc. - Common Stock was at 03/13/26 02:33 PM ET

What is the market capitalization of ImmunityBio, Inc. - Common Stock?

The market capitalization of ImmunityBio, Inc. - Common Stock is 3.32B

How many shares of ImmunityBio, Inc. - Common Stock are outstanding?

ImmunityBio, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.